DBV TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.186 EUR | -1.17% |
|
-4.35% | -35.86% |
| Sales 2024 * | 6.53M 6.99M 583M | Sales 2025 * | 4.89M 5.22M 436M | Capitalization | 114M 122M 10.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -107M -114M -9.54B | Net income 2025 * | -74M -79.12M -6.6B | EV / Sales 2024 * | -8.63 x |
| Net cash position 2024 * | 170M 182M 15.21B | Net cash position 2025 * | 224M 239M 19.96B | EV / Sales 2025 * | -22.4 x |
| P/E ratio 2024 * |
-1.54
x | P/E ratio 2025 * |
-2.76
x | Employees | 105 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on DBV Technologies
More press releases
More news
| 1 day | -1.17% | ||
| 1 week | -4.35% | ||
| Current month | -10.89% | ||
| 1 month | -10.89% | ||
| 3 months | -34.62% | ||
| 6 months | -44.21% | ||
| Current year | -35.86% |
1 week
1.18
1.25
1 month
1.181.40
Current year
1.101.90
1 year
1.104.30
3 years
1.1011.70
5 years
1.1025.44
10 years
1.1086.64
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tassé
CEO | Chief Executive Officer | 64 | 29/18/29 |
| Director of Finance/CFO | 54 | 06/11 | |
Pharis Mohideen
CTO | Chief Tech/Sci/R&D Officer | 59 | 22/19/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 01/21/01 |
Michel de Rosen
CHM | Chairman | 73 | 22/18/22 |
Don Soland
BRD | Director/Board Member | 65 | 06/15/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.186 | -1.17% | 37,915 |
| 25/24/25 | 1.2 | -0.99% | 26,014 |
| 24/24/24 | 1.212 | +0.33% | 32,502 |
| 23/24/23 | 1.208 | -0.17% | 32,514 |
| 22/24/22 | 1.21 | -2.42% | 53,978 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Sector
Pharmaceuticals
Calendar
02/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.186
EUR
Average target price
4.783
EUR
Spread / Average Target
+303.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.86% | 122M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- DBV Stock
